Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024).
Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 386, 1341–1352 (2015).
AlFakeeh, A. & Brezden-Masley, C. Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr. Oncol. 25, S18–S27 (2018).
Google Scholar
Early et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771–784 (2011).
Google Scholar
Pan, H. et al. 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N. Engl. J. Med. 377, 1836–1846 (2017).
Google Scholar
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365, 1687–1717 (2005).
Clarke, R., Tyson, J. J. & Dixon, J. M. Endocrine resistance in breast cancer—an overview and update. Mol. Cell. Endocrinol. 418, 220–234 (2015).
Google Scholar
Belachew, E. B. & Sewasew, D. T. Molecular mechanisms of endocrine resistance in estrogen-positive breast cancer. Front. Endocrinol. (Lausanne) 12, 599586 (2021).
Google Scholar
Miranda, F., Prazeres, H., Mendes, F., Martins, D. & Schmitt, F. Resistance to endocrine therapy in HR+ and/or HER2+ breast cancer: the most promising predictive biomarkers. Mol. Biol. Rep. 49, 717–733 (2022).
Google Scholar
Makhlin, I. et al. Targeted therapies, sequencing strategies, and beyond in metastatic hormone receptor-positive breast cancer: ASCO Guideline Clinical Insights. JCO Oncol. Pract. 21, 140–144 (2025).
Google Scholar
Corti, C., Rugo, H. S. & Tolaney, S. M. Decoding clinical trials in metastatic breast cancer: practical insights for optimal therapy sequencing. Am. Soc. Clin. Oncol. Educ. Book 45, e100053 (2025).
Google Scholar
Siegel, M. B. et al. Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J. Clin. Investig. 128, 1371–1383 (2018).
Google Scholar
Aftimos, P. et al. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. Cancer Discov. 11, 2796–2811 (2021).
Google Scholar
Ghosh, A. et al. Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2− breast tumours. Commun. Biol. 8, 207 (2025).
Google Scholar
Goswami, R. S. et al. Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin. Cancer Res. 21, 2644–2651 (2015).
Google Scholar
Meric-Bernstam, F. et al. Concordance of genomic alterations between primary and recurrent breast cancer. Mol. Cancer Ther. 13, 1382–1389 (2014).
Google Scholar
Bertucci, F. et al. Comparative genomic analysis of primary tumors and metastases in breast cancer. Oncotarget 7, 27208–27219 (2016).
Google Scholar
van Geelen, C. T. et al. Clinical implications of prospective genomic profiling of metastatic breast cancer patients. Breast Cancer Res. 22, 91 (2020).
Google Scholar
Yates, L. R. et al. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell 32, 169–184.e7 (2017).
Google Scholar
Brown, D. et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat. Commun. 8, 14944 (2017).
Google Scholar
Henry, N. L. et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO Guideline Update. J. Clin. Oncol. 40, 3205–3221 (2022).
Google Scholar
Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446–1451 (2013).
Google Scholar
Dustin, D., Gu, G. & Fuqua, S. A. W. ESR1 mutations in breast cancer. Cancer 125, 3714–3728 (2019).
Google Scholar
Fujii, T. et al. Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. Eur. J. Cancer 89, 64–71 (2018).
Google Scholar
Razavi, P. et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34, 427–438.e6 (2018).
Google Scholar
Jin, L. et al. The evolving landscape of genetic biomarkers for immunotherapy in primary and metastatic breast cancer. Front. Oncol. 15, 1522262 (2025).
Google Scholar
Angus, L. et al. The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies. Nat. Genet. 51, 1450–1458 (2019).
Google Scholar
Chaubal, R. et al. Genomic landscape of hormone therapy-resistant HR-positive, HER2-negative breast cancer. Breast Cancer Res. Treat. 213, 247–259 (2025).
Google Scholar
Mao, P. et al. Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER metastatic breast cancer. Clin. Cancer Res. 26, 5974–5989 (2020).
Google Scholar
Condorelli, R. et al. Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 30, 365–373 (2019).
Google Scholar
Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895–1902 (2018).
Google Scholar
Mankor, J. M. et al. Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples. Br. J. Cancer 122, 953–956 (2020).
Google Scholar
Ahmed, J., Das, B., Shin, S. & Chen, A. Challenges and future directions in the management of tumor mutational burden-high (TMB-H) advanced solid malignancies. Cancers (Basel) 15, 5841 (2023).
Büttner, R. et al. Implementing TMB measurement in clinical practice: considerations on assay requirements. ESMO Open 4, e000442 (2019).
Google Scholar
Mosele, F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 31, 1491–1505 (2020).
Google Scholar
Martínez-Jiménez, F. et al. Pan-cancer whole-genome comparison of primary and metastatic solid tumours. Nature 618, 333–341 (2023).
Google Scholar
Houlahan, K. E. et al. Complex rearrangements fuel ER and HER2 breast tumours. Nature 638, 510–518 (2025).
Google Scholar
Hieronymus, H. et al. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death. Elife 7, e37294 (2018).
Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701–708 (2020).
Google Scholar
Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
Google Scholar
Sørlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 98, 10869–10874 (2001).
Google Scholar
Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160–1167 (2009).
Google Scholar
Loi, S. et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J. Clin. Oncol. 25, 1239–1246 (2007).
Google Scholar
Inic, Z. et al. Difference between luminal A and luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information. Clin. Med. Insights Oncol. 8, 107–111 (2014).
Google Scholar
Lafcı, O., Celepli, P., Seher Öztekin, P. & Koşar, P. N. DCE-MRI radiomics analysis in differentiating luminal A and luminal B breast cancer molecular subtypes. Acad. Radiol. 30, 22–29 (2023).
Google Scholar
Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Hanker, A. B., Sudhan, D. R. & Arteaga, C. L. Overcoming endocrine resistance in breast cancer. Cancer Cell 37, 496–513 (2020).
Google Scholar
Cortesi, L., Rugo, H. S. & Jackisch, C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 16, 255–282 (2021).
Google Scholar
Shao, C. et al. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies. Environ. Mol. Mutagen. 63, 308–316 (2022).
Google Scholar
Bertucci, F. et al. Genomic characterization of metastatic breast cancers. Nature 569, 560–564 (2019).
Google Scholar
Winter, C. et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann. Oncol. 27, 1532–1538 (2016).
Google Scholar
Vidula, N. eelima et al. Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC). J. Clin. Oncol. 41, TPS1134–TPS1134 (2023).
Google Scholar
Tung, N. M. et al. TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J. Clin. Oncol. 38, 4274–4282 (2020).
Google Scholar
Barroso-Sousa, R. et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann. Oncol. 31, 387–394 (2020).
Google Scholar
Barroso-Sousa, R., Pacífico, J. P., Sammons, S. & Tolaney, S. M. Tumor mutational burden in breast cancer: current evidence, challenges, and opportunities. Cancers (Basel) 15, 3997 (2023).
Schnidrig, D., Turajlic, S. & Litchfield, K. Tumour mutational burden: primary versus metastatic tissue creates systematic bias. Immunooncol. Technol. 4, 8–14 (2019).
Google Scholar
Schagerholm Stanev, C. et al. Transcriptomic profiles of endocrine-resistant breast cancer. BMC Cancer 25, 1556 (2025).
Google Scholar
Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J. Clin. Oncol. 38, 1346–1366 (2020).
Google Scholar
Jones, R. et al. A Phase I/II trial of *oral SRA737 (a Chk1 Inhibitor) given in combination with low-dose gemcitabine in patients with advanced cancer. Clin. Cancer Res. 29, 331–340 (2023).
Google Scholar
Kim, H. et al. TNFα enhances tamoxifen sensitivity through dissociation of ERα-p53-NCOR1 complexes in ERα-positive breast cancer. Cancers (Basel) 13, (2021).
Zhao, H. et al. Identifying enhancer-driven subtype-specific prognostic markers in breast cancer based on multi-omics data. Front. Immunol. 13, 990143 (2022).
Google Scholar
Oh, E. et al. Comparison of accuracy of whole-exome sequencing with formalin-fixed paraffin-embedded and fresh frozen tissue samples. PLoS ONE 10, e0144162 (2015).
Google Scholar
Hedegaard, J. et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS ONE 9, e98187 (2014).
Google Scholar
Lyander, A., Gellerbring, A., Hägglund, M., Elhami, K. & Wirta, V. NGS method for parallel processing of high quality, damaged or fragmented input material using target enrichment. PLoS ONE 19, e0304411 (2024).
Google Scholar
Schagerholm, C., Robertson, S., Toosi, H., Sifakis, E. G. & Hartman, J. PIK3CA mutations in endocrine-resistant breast cancer. Sci. Rep. 14, 12542 (2024).
Google Scholar
Zhao, X., Rødland, E. A., Tibshirani, R. & Plevritis, S. Molecular subtyping for clinically defined breast cancer subgroups. Breast Cancer Res. 17, 29 (2015).
Google Scholar
R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2026). https://www.R-project.org/.
Yang, Q., Hartman, J. & Sifakis, E. G. BreastSubtypeR: a unified R/Bioconductor package for intrinsic molecular subtyping in breast cancer research. NAR Genom. Bioinform. 7, lqaf131 (2025).
Google Scholar
Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105–113 (2010).
Google Scholar
Salgado, R. et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann. Oncol. 26, 259–271 (2015).
Google Scholar
Tarantino, P. et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann. Oncol. 34, 645–659 (2023).
Google Scholar
Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
Google Scholar
Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
Google Scholar
NanoString Technologies. nCounter® Human Breast Cancer 360™ V2 Panel [Gene List] (Bruker Spatial Biology). https://brukerspatialbiology.com/products/ncounter-assays-panels/ncounter-rna-assays/oncology/breast-cancer-360/.
Fernandez-Martinez, A. et al. Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials. JAMA Oncol. 9, 490–499 (2023).
Google Scholar
Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).
Google Scholar
Canisius, S., Martens, J. W. M. & Wessels, L. F. A. A novel independence test for somatic alterations in cancer shows that biology drives mutual exclusivity but chance explains most co-occurrence. Genome Biol. 17, 261 (2016).
Google Scholar
Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 44, e131 (2016).
Google Scholar
Auwerx, C. et al. The individual and global impact of copy-number variants on complex human traits. Am. J. Hum. Genet. 109, 647–668 (2022).
Google Scholar
Nguyen, M. P. et al. Pan-cancer copy number analysis identifies optimized size thresholds and co-occurrence models for individualized risk stratification. Nat. Commun. 16, 6024 (2025).
Google Scholar
Microsoft Corporation. Microsoft® Excel® for Microsoft 365 MSO. Available from: https://www.microsoft.com/sv-se/microsoft-365/excel.
